Trial
NCT02706405
JCAR014 and Durvalumab in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Fred Hutchinson Cancer Center
Collaborators
AstraZeneca; Juno Therapeutics, Inc., a Bristol-Myers Squibb Company; MedImmune LLC; National Cancer Institute (NCI)
Condition
Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
Intervention
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014
Why stopped
Terminated due to slow accrual.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2022-08-24